HBV News and Research

RSS

Altered T-cell response in hemodialysis patients following third COVID-19 vaccine dose

Scientists define the immune responses against COVID-19 in HD patients who received three mRNA COVID-19 vaccine doses.

13 Sep 2022

New immunological treatment against hepatitis B and D viruses shows promising results in animal models

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models.

26 Aug 2022

Immune therapy may be an alternate therapeutic approach for treating chronic hepatitis B

Hepatitis B virus (HBV) infection is global in nature and induces several incredible liver diseases, such as chronic hepatitis B (CHB), cirrhosis of the liver (LC) and hepatocellular carcinoma (HCC). A total of 882,000 patients died of HBV-related liver diseases in 2019.

25 Aug 2022

NIH updates its strategic plan for hepatitis B research

The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care.

1 Aug 2022

World Hepatitis Day 2022: Why Accelerating the Fight Against Hepatitis Cannot Wait

In our latest interview, News-Medical speaks to Simon Parker, an infectious disease specialist, about hepatitis C diagnostics and testing, as well as why the global fight against hepatitis cannot wait.

28 Jul 2022

The Mark Foundation for Cancer Research announces latest ASPIRE awards for eight outstanding projects

The Mark Foundation for Cancer Research announced eight outstanding research projects to receive its latest class of ASPIRE awards.

14 Jul 2022

Impact of SARS-CoV-2 infection on menstrual cycle

Researchers systematically reviewed the impact of COVID-19 on the menstrual cycle.

4 Jul 2022

Two broadly neutralizing antibodies show promise to provide long-acting immunity against SARS-CoV-2

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

15 Jun 2022

Etiologies of liver cancer are changing and the prognosis is mixed, study says

The primary causes of liver cancer are well known: viral (hepatitis B and C), alcohol and non-alcoholic steatohepatitis (NASH), a condition in which fat builds up in the liver, resulting in chronic inflammation and damage.

7 Jun 2022

Racism may partly contribute to high cancer burden impacting Asian Americans

The Journal of the National Cancer Institute published a commentary today on the significant cancer disparities facing Asian Americans.

19 Apr 2022

Recent advances in non-viral nano-vector delivery of CRISPR/Cas9 genome editing payloads

Researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing system.

14 Apr 2022

UCL researchers boost the effectiveness of therapeutic vaccine for chronic HBV

Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.

13 Apr 2022

Using CRISPR/Cas to develop biosafety materials

Researchers discuss the use of the highly efficient CRISPR/Cas technologies to identify viral genome sequences for biosafety purposes.

21 Mar 2022

Immunomolecular detection method to rapidly and accurately detect complete SARS-CoV-2 virions

Researchers developed a hybrid assay incorporating immunological antibody-based viral spike protein capture with molecular nucleic acid amplification by qRT-PCR.

24 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Researchers generate stable cell lines capable of producing various hepatitis B virus genotypes

A new study created stable cell lines capable of producing different genotypes of the hepatitis B virus (HBV), advancing understanding of each type's distinct virological features, treatment responses, and infectivity that could lead to new therapies against a virus infecting humans as far back as 4,500 years ago.

15 Feb 2022

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Scientists have recently used synthetic biology to design primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors (ACE2 CAR or anti-Spike CAR).

25 Jan 2022

Plant-derived virus-like particle vaccines against SARS-CoV-2

In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.

1 Dec 2021

Third dose of Covid-19 vaccine benefits dialysis patients

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot.

28 Oct 2021

Study traces the evolution of hepatitis B virus since prehistoric times

A study published in the journal Science traces the evolution of the hepatitis B virus from prehistory to the present, revealing dissemination routes and changes in viral diversity. Domingo Carlos Salazar García, researcher from the Prehistory, Archeology and Ancient History Department of the University of Valencia, has participated in this study led by the Max Planck Institute for the Science of Human History (Germany).

8 Oct 2021